Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Keith A. Goldan Sells 1,296 Shares

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) CFO Keith A. Goldan sold 1,296 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $9.29, for a total value of $12,039.84. Following the sale, the chief financial officer owned 92,450 shares in the company, valued at $858,860.50. This represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Syndax Pharmaceuticals Stock Performance

Syndax Pharmaceuticals stock traded up $0.58 during mid-day trading on Tuesday, hitting $10.31. 1,892,314 shares of the company's stock traded hands, compared to its average volume of 1,878,889. The firm has a 50 day moving average price of $9.86 and a 200 day moving average price of $12.13. The company has a quick ratio of 5.75, a current ratio of 5.80 and a debt-to-equity ratio of 1.53. The company has a market cap of $887.18 million, a PE ratio of -2.67 and a beta of 0.70. Syndax Pharmaceuticals, Inc. has a one year low of $8.58 and a one year high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.06. Syndax Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 757.53%. The firm had revenue of $20.04 million for the quarter, compared to the consensus estimate of $15.88 million. During the same quarter in the previous year, the business earned ($0.85) EPS. The firm's revenue for the quarter was up 1900.0% on a year-over-year basis. On average, equities analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Quarry LP purchased a new position in shares of Syndax Pharmaceuticals during the first quarter valued at $25,000. Virtus ETF Advisers LLC grew its stake in Syndax Pharmaceuticals by 18.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock valued at $70,000 after purchasing an additional 827 shares in the last quarter. Magnetar Financial LLC purchased a new position in Syndax Pharmaceuticals in the first quarter valued at about $132,000. Optimize Financial Inc purchased a new position in Syndax Pharmaceuticals in the fourth quarter valued at about $152,000. Finally, Lazard Asset Management LLC purchased a new position in Syndax Pharmaceuticals in the fourth quarter valued at about $153,000.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Wall Street Zen upgraded Syndax Pharmaceuticals to a "sell" rating in a research report on Tuesday, May 6th. Scotiabank lifted their target price on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a research report on Tuesday, May 6th. Guggenheim reiterated a "buy" rating and issued a $32.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, May 6th. UBS Group decreased their target price on Syndax Pharmaceuticals from $37.00 to $35.00 and set a "buy" rating for the company in a research report on Tuesday, July 15th. Finally, The Goldman Sachs Group began coverage on Syndax Pharmaceuticals in a research report on Thursday, July 10th. They issued a "buy" rating and a $18.00 target price for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $34.10.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).